Open access
Sep 2026
307. A new nanoformulation of a brain-penetrating VIPR2 antagonist peptide for the treatment of schizophrenia
Abstract Background Both preclinical and clinical studies have demonstrated a strong link between high expression/overactivation of vasoactive intestinal peptide receptor 2 (VIPR2) and schizophrenia. We recently reported on a brain-penetrant formulation of the VIPR2 antagonist peptide KS-133, which was found to restore...
Y. Ago, Z. Jin, D. Koan et al.
· International Journal of Neu... · 0 citations